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Abstract Little is known about enteropathogen seroepidemiology among children in low-
resource settings. We measured serological IgG responses to eight enteropathogens (Giardia
intestinalis, Cryptosporidium parvum, Entamoeba histolytica, Salmonella enterica, enterotoxigenic
Escherichia coli, Vibrio cholerae, Campylobacter jejuni, norovirus) in cohorts from Haiti, Kenya, and
Tanzania. We studied antibody dynamics and force of infection across pathogens and cohorts.
Enteropathogens shared common seroepidemiologic features that enabled between-pathogen
comparisons of transmission. Overall, exposure was intense: for most pathogens the window of
primary infection was <3 years old; for highest transmission pathogens primary infection occurred
within the first year. Longitudinal profiles demonstrated significant IgG boosting and waning above
seropositivity cutoffs, underscoring the value of longitudinal designs to estimate force of infection.
Seroprevalence and force of infection were rank-preserving across pathogens, illustrating the
measures provide similar information about transmission heterogeneity. Our findings suggest
antibody response can be used to measure population-level transmission of diverse
enteropathogens in serologic surveillance.
DOI: https://doi.org/10.7554/eLife.45594.001
Introduction
A broad set of viral, bacterial, and parasitic enteropathogens are leading causes of the global infec-
tious disease burden, with the highest burden among young children living in lower income countries
(GBD 2016 DALYs and HALE Collaborators, 2016). Infections that result in acute diarrhea and
related child deaths drive disease burden estimates attributed to enteropathogens, but
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asymptomatic infections are extremely common and the full scope of sequelae is only partially
understood (Liu et al., 2016; Platts-Mills et al., 2018). Much of what we know about enteropatho-
gen transmission is based on passive clinical surveillance, which reflects a small fraction of all infec-
tions. For example, antibody-based incidence of infection to Salmonella enterica and Campylobacter
jejuni were 2–6 orders of magnitude higher than case-based surveillance in European populations
(Simonsen et al., 2008; Falkenhorst et al., 2012; Teunis et al., 2012; Teunis et al., 2013), and a
study of Salmonella enterica serotype Typhi in Fiji found similarly high discordance between anti-
body-based incidence and case-based surveillance (Watson et al., 2017). A more complete picture
of enteropathogen infection in populations would help understand drivers of transmission, disease
burden, naturally acquired immunoprotection, as well as to design public health prevention meas-
ures, and measure intervention effects.
Stool-based, high-throughput PCR assays have helped solve the logistical difficulties of single-
pathogen testing for enterics and have provided new insights into pathogen-specific infections and
disease burden (Liu et al., 2016; Platts-Mills et al., 2018). Yet, stool is not routinely collected in
population-based surveys, and infection with many globally important enteric pathogens can be suf-
ficiently rare and relatively short-lived to require designs with almost continuous surveillance (Platts-
Mills et al., 2018; Lin et al., 2018). At the same time, large-scale serological surveillance platforms
create new opportunities for expanded enteropathogen surveillance alongside other infectious dis-
eases (Metcalf et al., 2016; Arnold et al., 2018). These challenges and opportunities have gener-
ated interest in antibody-based measurement as a complement to PCR for population-based
enteropathogen surveillance (Griffin et al., 2011; Exum et al., 2016; Moss et al., 2014;
Arnold et al., 2017), and for endpoints in observational and randomized studies (Crump et al.,
2007; Zambrano et al., 2017; Chard et al., 2018; Vargas et al., 2017; Mosites et al., 2018;
Wade et al., 2018; Egorov et al., 2018).
eLife digest Diarrhea, which is caused by bacteria such as Salmonella or by viruses like
norovirus, is the fourth leading cause of death among children worldwide, with children in low-
resource settings being at highest risk. The pathogens that cause diarrhea spread when stool from
infected people comes into contact with new hosts, for example, through inadequate sanitation or
by drinking contaminated water. Currently, the best way to track these infections is to collect stool
samples from people and test them for the presence of the pathogens. Unfortunately, this is costly
and difficult to do on a large scale outside of clinical settings, making it hard to track the spread of
diarrhea-causing pathogens.
The body produces antibodies – small proteins that can detect specific pathogens – in response
to an infection. These antibodies help ward off future infections by the same pathogen, so if they are
present in the blood, this indicates a current or previous infection. Scientists already collect blood
samples to track malaria, HIV and vaccine-preventable diseases in low-resource settings. These
samples could be tested more broadly to measure the levels of antibodies against diarrhea-causing
pathogens.
Now, Arnold et al. have used blood samples collected from children in Haiti, Kenya, and Tanzania
to measure antibody responses to 8 diarrhea-causing pathogens. The results showed that many
children in these settings had been infected with all 8 pathogens before age three, and that all of
the pathogens shared similar age-dependent patterns of antibody response. This finding enabled
Arnold et al. to combine antibody measurements with statistical models to estimate each
pathogen’s force of infection, that is, the rate at which susceptible individuals in the population
become infected. This is a key step for epidemiologists to understand which pathogens cause the
most infections in a population.
The experiments show that testing blood samples for antibodies could provide scientists with a
new tool to track the transmission of diarrhea-causing pathogens in low-resource settings. This
information could help public health officials design and test efforts to prevent diarrhea, for
example, by improving water treatment or developing vaccines.
DOI: https://doi.org/10.7554/eLife.45594.002
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After infection, many enteropathogens elicit a transiently elevated antibody response that wanes
over time. In lower transmission settings where antibody responses could be monitored longitudi-
nally after distinct infections, Salmonella enterica, Campylobacter jejuni, Cryptosporidium parvum,
and Giardia intestinalis (syn. Giardia lamblia, Giardia duodenalis) immunoglobulin G (IgG) levels in
blood have been shown to wane over a period of months since infection; IgM and IgA levels decline
even more quickly (Teunis et al., 2012; Strid et al., 2001; Priest et al., 2001; Priest et al., 2010;
Falkenhorst et al., 2013; Hjøllo et al., 2018). Compared with permanently immunizing infections
such as measles, transient immunity adds a layer of complexity to seroepidemiologic inference and
methods. To our knowledge, there has been no detailed study of enteropathogen seroepidemiology
among children in low-resource settings where transmission is intense beginning early in life (Platts-
Mills et al., 2018). Such studies are needed to determine if serology is a viable approach to measure
enteropathogen transmission in low-resource settings.
We conducted a series of analyses in cohorts from Haiti, Tanzania, and Kenya that measured sero-
logical antibody responses to eight enteropathogens using multiplex bead assays. Our objectives
were to identify common patterns in antibody dynamics shared across enteropathogens and popula-
tions, and to evaluate serological methods to compare between-pathogen heterogeneity in infec-
tion, including estimates of force of infection. Our results provide new insights into the
seroepidemiology of enteropathogens among children living in low-resource settings, and contrib-
ute advances to inform the design and analysis of surveillance efforts whose goal is to quantify het-
erogeneity in enteropathogen transmission through antibody response.
Results
Study populations
The analysis included measurements from cohorts in Haiti, Kenya, and Tanzania. Blood specimens
were tested for IgG levels to eight enteropathogens using a multiplex bead assay on the Luminex
platform (Table 1). The Haitian cohort included repeated measurements among children enrolled in
a study of lymphatic filariasis transmission in Leogane from 1990 to 1999 (Lammie et al., 1998;
Hamlin et al., 2012). Leogane is a coastal agricultural community west of Port au Prince. At the time
of the study its population was approximately 15,000, most homes had no electricity and none had
running water. In total, the Haiti study tested 771 finger prick blood specimens collected from 142
children ages birth to 11 years old, with each measurement typically separated by one year (median
measurements per child: 5; range: 2 to 9). In Kenya, a 2013 prospective trial of locally-produced, in-
home ceramic water filters enrolled 240 children in a serological substudy (Morris et al., 2018).
Study participants were identified through the Asembo Health and Demographic Surveillance Sys-
tem, which is located in a rural part of Siaya County, western Kenya along the shore of Lake Victoria.
Only 29% of the population had piped drinking water (public taps), water source contamination with
E. coli prevailed (93% of samples tested), and the average age children began consuming water was
4 months (Morris et al., 2018). Children aged 4 to 10 months provided dried blood spot specimens
at enrollment (February 2013), and again 6 to 7 months later (August to September, 2013; n = 205
children measured longitudinally). The Kenya study period encompassed seasonally heavy rains from
March through June. In Tanzania, 96 independent clusters across eight trachoma-endemic villages in
the Kongwa region were enrolled in a randomized trial to study the effects of annual azithromycin
distribution on Chlamydia trachomatis infection (Wilson et al., 2019). The population is very rural,
and water is scarce in the region: at enrollment, 69% of participants reported their primary drinking
water source, typically an unprotected spring, was >30 min’ walk one-way. From 2012 to 2015, the
Tanzania study collected dried blood spots from between 902 and 1577 children ages 1–9 years old
in annual cross-sectional surveys that took place from October through December at the conclusion
of the dry season before heavy seasonal rains (total measurements: 4,989). Although children could
have been measured repeatedly over the four-year study in Tanzania, they were not tracked longitu-
dinally. There was no evidence that the Kenya and Tanzania interventions reduced enteropathogen
antibody response (Supplementary file 1), so this analysis pooled measurements from the study
arms in each population.
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Table 1. Number of children and samples tested, and estimated seropositivity cutoffs by country
and antigen included in the seroepidemiologic analyses.
Seropositivity cutoff, log10 IgG (MFI-bg) *
N N External Mixture Presumed
children samples Reference Model Unexposed
Leogane, Haiti
Giardia VSP-3 142 771 2.42 1.64 2.11
Giardia VSP-5 142 771 2.31 1.46 1.88
Cryptosporidium Cp17 142 771 2.26 2.00 2.58
Cryptosporidium Cp23 142 771 2.70 2.75 2.57
E. histolytica LecA 142 771 2.48 2.30 1.93
Salmonella LPS group B 142 771 1.60 1.37
Salmonella LPS group D 142 771 1.48 2.48
ETEC LT B subunit 142 771 2.86
Norovirus GI.4 142 771 2.51 2.09
Norovirus GII.4.NO 142 771 2.04 2.24
Asembo, Kenya
Giardia VSP-3 240 445 2.81 1.62 1.67
Giardia VSP-5 240 445 2.65 1.82 1.67
Cryptosporidium Cp17 240 445 2.63 2.58 2.38
Cryptosporidium Cp23 240 445 3.14 3.40 2.36
E. histolytica LecA 240 445 1.89
Salmonella LPS group B 240 445 1.36
Salmonella LPS group D 240 445 1.41
ETEC LT B subunit 240 445 2.79
Cholera toxin B subunit 240 445 2.91
Campylobacter p18 240 445 2.11
Campylobacter p39 240 445 2.61 2.57
Kongwa, Tanzania
Giardia VSP-3 4989 4989 2.23 2.04
Giardia VSP-5 4989 4989 2.15 2.27
Cryptosporidium Cp17 4989 4989 2.26
Cryptosporidium Cp23 4989 4989 2.58
E. histolytica LecA 4989 4989 1.97 2.50
Salmonella LPS group B† 902 902
Salmonella LPS group D† 902 902
ETEC LT B subunit 4989 4989
Cholera toxin B subunit‡ 4087 4087
Campylobacter p18† 902 902
Campylobacter p39† 902 902
*Seropositivity cutoffs determined using external reference samples (typically ROC curves except for Giardia and E.
hystolitica in Haiti), finite Gaussian mixture models, or distribution among the presumed unexposed (see
Materials and methods for details). External reference cutoffs vary across cohorts for the same antigen due to use of
different bead sets in each cohort. External reference cutoffs reported from years (2013–2015) in Tanzania, estimated
among 4087 samples. Cutoff values are missing if they could not be estimated in each method; cutoff values based
on the presumed unexposed required longitudinal measurements within individual children and therefore could not
be estimated for any antigen in the repeated cross-sectional design in Tanzania.
† Measured only in year 1 of the study (2012).
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Age-dependent shifts in population antibody distributions
We estimated seropositivity cutoffs using three approaches: receiver operator characteristic (ROC)
curve analyses for Giardia, Cryptosporidium, and Entamoeba histolytica including a panel of exter-
nal, known positive and negative specimens, as previously reported (Moss et al., 2014;
Morris et al., 2018); Gaussian mixture models (Benaglia et al., 2009) fit to measurements among
children ages 0–1 year old to ensure a sufficient number of unexposed children; and, presumed sero-
negative distributions among children who experienced large increases in antibody levels (Table 1).
Classification agreement was high between the different approaches (agreement >95% for most
comparisons; Supplementary file 2).
Among children < 2 years old, antibody levels clearly distinguished seronegative and seropositive
subpopulations, but there were not distinct seronegative and seropositive subpopulations by age 3
years for most pathogens measured in Haiti (Figure 1) and Tanzania (Figure 1—figure supplement
1). By age 3 years, the majority of children were seropositive to Cryptosporidium, enterotoxigenic
Escherichia coli heat labile toxin B subunit (ETEC LT B subunit), and norovirus GI.4 and GII.4; in all
cases antibody distributions were shifted above seropositivity thresholds. In contrast, there was a
qualitative change in the antibody response distributions to Giardia, E. histolytica, Salmonella and
‡ Measured only in years 2–4 of the study (2013–2015).
DOI: https://doi.org/10.7554/eLife.45594.003
Figure 1. Age-stratified, IgG distributions among a longitudinal cohort of 142 children ages birth to 11 years in Leogane, Haiti, 1990 – 1999. IgG
response measured in multiplex using median fluorescence units minus background (MFI-bg) on the Luminex platform in 771 specimens, marked with
rug plots below each distribution. Vertical lines mark seropositivity cutoffs are based on ROC analyses (solid), finite Gaussian mixture models (heavy
dash), or distribution among presumed unexposed (light dash). Mixture models failed to converge for ETEC LT B subunit. Created with notebook
(https://osf.io/dk54y) and data (https://osf.io/3nv98). Figure 1—figure supplement 1 shows similar distributions from the Tanzania study. Figure 1—
figure supplement 2 contrasts Giardia VSP-3 distributions with trachoma pgp3 distributions. Figure 1—figure supplement 3 shows distributions from
the Kenyan cohort.
DOI: https://doi.org/10.7554/eLife.45594.004
The following figure supplements are available for figure 1:
Figure supplement 1. Age-stratified, IgG distributions among 4989 children ages 1 to 9 years old in Kongwa, Tanzania, 2012 2015.
DOI: https://doi.org/10.7554/eLife.45594.005
Figure supplement 2. Contrasting age-dependent changes in distributions of IgG levels to Giardia VSP-3 and Chlamydia trachomatis pgp3 antigens
among 4989 children ages 1 to 9 years old in Kongwa, Tanzania, 2012 – 2015.
DOI: https://doi.org/10.7554/eLife.45594.006
Figure supplement 3. IgG distributions among children ages 4 to 17 months old in Asembo, Kenya, 2013.
DOI: https://doi.org/10.7554/eLife.45594.007
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Campylobacter with increasing age, shifting from a bimodal distribution of seronegative and sero-
positive groups among children  1 year old to a unimodal distribution by age 3 years and older
(Figure 1, Figure 1—figure supplement 1). A direct comparison of age-dependent shifts in anti-
body distributions to Giardia VSP-3 antigen and Chlamydia trachomatis pgp3 antigen in Tanzania
illustrates stark differences in enteropathogen- generated immune responses versus pathogens like
Chlamydia that elicit a response that consistently differentiates exposed and unexposed subpopula-
tions as children age (Figure 1—figure supplement 2). Distributions of IgG levels in the younger
Kenyan cohort (ages 4–17 months) showed distinct groups of seropositive and seronegative meas-
urements for most antigens (Figure 1—figure supplement 3). IgG responses to ETEC LT B subunit
and cholera toxin B subunit were near the maximum of the dynamic range of the assay for nearly all
children measured in the three cohorts (Figure 1, Figure 1—figure supplement 1, Figure 1—figure
supplement 3), and these IgG levels waned as children aged, presumably from acquired immunity
(Figure 1, Figure 1—figure supplement 1).
Joint variation in antibody response
We hypothesized that IgG responses to closely related antigens would co-vary but that IgG
responses to unrelated antigens would be uncorrelated. Joint variation in individual-level IgG
responses aligned with hypothesized relationships based on antigenic overlap and shared epitopes.
Responses to Giardia VSP antigens were strongly correlated in Haiti (Spearman rank: =0.99), Kenya
(=0.84) and Tanzania (=0.97), as would be expected for antigens with conserved conformational
epitopes (Figure 2). Cryptosporidium (Cp17, Cp23) and Campylobacter (p18, p39) antigens were
strongly correlated, but high within-individual variability suggests that measuring responses to multi-
ple unique recombinant protein antigens yields more information about infection than measuring
responses to one alone (Figure 2). High correlation between Salmonella LPS Groups B and D,
between norovirus GI.4 and GII.4, and between ETEC and V. cholerae likely reflected antibody
cross-reactivity. Correlation could also result from multiple previous infections with different Salmo-
nella serogroups or different norovirus genogroups. A comparison across all antigens revealed no
other combinations with high correlation (Supplementary file 3).
We excluded cholera toxin B subunit antibody responses from remaining analyses because of the
difficulty of interpreting its epidemiologic measures in light of high levels of cross-reactivity with
ETEC LT B subunit. Heat labile toxin-producing ETEC is very common among children in low-
resource settings (Platts-Mills et al., 2018), and there was no documented transmission of cholera
in the study populations during measurement periods.
Birth to three years of age: a key window of antibody acquisition and
primary seroconversion
For most pathogens, mean IgG levels and seroprevalence rose quickly and plateaued by ages 1 to 3
years in Haiti (Figure 3), Kenya (Figure 3—figure supplement 1), and Tanzania (Figure 3—figure
supplement 2). Despite enormous individual-level variation, age-dependent mean IgG curves exhib-
ited characteristic shapes seen across diverse pathogens, and reflected high levels of early-life expo-
sure (Arnold et al., 2017). In Haiti, seroprevalence ranged from 66% (E. histolytica) to 100% (ETEC
LT B subunit) by age 3 years (Figure 3B), and in Tanzania, the majority of 1 year olds were already
seropositive for Giardia (77%) and Cryptosporidium (85%) (Figure 3—figure supplement 2B). There
was some evidence of maternally-derived IgG among children under 6 months old with a drop in
mean IgG levels by age, but this pattern was only evident for norovirus GI.4 in Haiti (Figure 3A) and
Cryptosporidium Cp17 and Cp23 in Kenya (Figure 3—figure supplement 1A). Age-dependent
mean IgG responses to many pathogens declined from a young age, presumably from exposure
early in life and acquired immunity. Mean IgG levels declined after age 1 year for Giardia in Haiti
(Figure 3A), Giardia and Campylobacter in Tanzania (Figure 3—figure supplement 2A).
Longitudinal antibody dynamics show significant boosting and waning
above seropositivity cutoffs
Based on age-dependent shifts in IgG distributions (Figure 1), we hypothesized that conversion of
IgG levels to seropositive and seronegative status could mask important dynamics of enteropatho-
gen immune response above seropositivity cutoffs, particularly among ages beyond the window of
Arnold et al. eLife 2019;8:e45594. DOI: https://doi.org/10.7554/eLife.45594 6 of 30
Research article Epidemiology and Global Health
Figure 2. Joint distributions of select enteric pathogen antibody responses among children in three cohorts from Haiti, Kenya, and Tanzania. Each
panel includes Spearman rank correlations () and locally weighted regression smoothers with default parameters, trimmed to 95% of the data to avoid
edge effects. Antibody response measured in multiplex using median fluorescence units minus background (MFI-bg) on the Luminex platform. Empty
Figure 2 continued on next page
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primary infection. In Haiti and Kenya we examined longitudinal IgG profiles among children. In the
Haitian cohort, which was followed beyond the window of primary infection, children commonly
had >4 fold increases and decreases in IgG while remaining above seropositivity cutoffs—a pattern
observed across pathogens but particularly clear for Cryptosporidium (Figure 4). In Kenya, 4-fold
increases in IgG largely coincided with a change in status from seronegative to seropositive, presum-
ably because increases in IgG followed primary infection in the young cohort ages 4–17 months (Fig-
ure 4—figure supplement 1). Many Kenyan children exhibited >4 fold increases and decreases in
IgG response to Campylobacter p18 and p39 antigens above the seropositivity cutoff, a result of
earlier primary infection and/or additional infection and boosting during the study period (Figure 4—
figure supplement 1).
Comparison of serology with stool-based measures of infection
The Kenya study monitored diarrhea symptoms in weekly visits between enrollment and follow-up.
The study collected stool from children whose caregivers reported diarrhea symptoms in the past 7
days, and tested stool for Cryptosporidium and Giardia infections using an immunoassay with addi-
tional PCR testing for Cryptosporidium as previously described (Morris et al., 2018). Among 132
children with paired serology measurements, those infected with Cryptosporidium (n = 17) and Giar-
dia (n = 25) enabled us to compare stool-based measures of infection with IgG responses. Children
with confirmed infections in diarrheal stools had higher IgG levels and seroprevalence at both time
points compared with those who did not have confirmed infections, but many children without stool-
confirmed infections seroconverted during the study. Among children without confirmed Giardia
infection in diarrheal stools, seroprevalence to VSP-3 or VSP-5 antigens increased from 1% (95% CI:
0%, 5%) at enrollment to 22% (14%, 32%) at follow-up; among children without confirmed Crypto-
sporidium infection, seroprevalence to Cp17 or Cp23 antigens increased from 16% (10%, 24%) at
enrollment to 47% (37%, 57%) at follow-up. These findings suggest that many children were not
shedding genetic material at the time of diarrheal stool collection, or many infections with these two
pathogens were asymptomatic. Supplementary file 4 includes additional details.
Serological estimates of force of infection
The seroconversion rate, an instantaneous rate of seroconversion among those who are susceptible,
is one estimate of a pathogen’s force of infection and a fundamental epidemiologic measure of
transmission (Hens et al., 2012). Serologically derived force of infection is useful for pathogens that
commonly present asymptomatically, such as many enteric infections. Across diverse pathogens,
steeper age-seroprevalence curves typically reflect higher transmission intensity (Corran et al.,
2007; Pinsent et al., 2018), and age-adjusted seroprevalence equals the area under the age-sero-
prevalence curve (a summary measure) (Arnold et al., 2017). We therefore hypothesized that sero-
prevalence and prospectively estimated force of infection should embed similar information about
infection heterogeneity across pathogens. We also hypothesized that standard methods to estimate
force of infection from age-structured seroprevalence would underestimate force of infection
derived from longitudinal data because of significant antibody boosting and waning above seroposi-
tivity cutoffs.
Longitudinal designs in Haiti and Kenya enabled us to use individual child antibody profiles to
estimate average rates of prospective seroconversion and seroreversion during the studies. We
defined incident seroconversions and seroreversions as a change in IgG across a pathogen’s sero-
positivity cutoff and estimated force of infection as incident changes in serostatus divided by per-
son-time at risk. In a secondary analysis, we defined incident boosting as a  4 fold increase in IgG
to a final level above a seropositivity cutoff and incident waning as 4 fold decrease in IgG from an
initial level above a seropositivity cutoff. The secondary definition captured large changes in IgG
Figure 2 continued
panels indicate that the antibodies were not measured in that cohort. Supplementary file 3 includes all pairwise comparisons. Created with notebook
(https://osf.io/hv9ce) and data (https://osf.io/3nv98, https://osf.io/2q7zg, https://osf.io/kv4d3).
DOI: https://doi.org/10.7554/eLife.45594.008
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Figure 3. Age dependent mean IgG and seroprevalence in Haiti. Geometric means (A) and seroprevalence (B), estimated with cubic splines among
children ages birth to 10 years in Leogane, Haiti 1990–1999. Shaded bands are approximate, simultaneous 95% confidence intervals. IgG response
measured in multiplex using median fluorescence units minus background (MFI-bg) on the Luminex platform (N = 771 measurements from 142
children). Created with notebook (https://osf.io/jeby3) and data (https://osf.io/3nv98). Data for some antigens measured among children < 5 years
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above seropositivity cutoffs, which aligned with repeated boosting and waning observed in the Hai-
tian cohort (Figure 4).
We found a rank-preserving relationship between pathogen seroprevalence and average force of
infection in Kenya and Haiti (Figure 5). Overall levels and steepness of the relationship differed
between cohorts, presumably because Kenya measurements were within a window of primary infec-
tion for most children (4–17 months) whereas Haiti measurements extended from birth to 11 years
and captured lower incidence periods with overall higher seroprevalence as children aged. Consis-
tent with this interpretation, when we progressively narrowed the age range of the Haitian cohort
and repeated the analysis, the relationship was steeper when estimated among children ages 0–2
years and flattened as measurements among older children were added (Figure 5—figure supple-
ment 1).
Force of infection varied widely across pathogens in Kenya, ranging from 0.1 seroconversions per
year for E. histolytica to >5 for Campylobacter (Figure 5). In Haiti, force of infection ranged from 0.3
E. histolytica seroconversions per year to 1.1 ETEC seroconversions per year (Figure 5). Force of
infection estimated from 4-fold changes in IgG led to more events and slightly higher rates com-
pared with those estimated from seroconversion alone (Table 2). For example, Cryptosporidium inci-
dent cases increased from 70 to 204 (a 2.9 fold increase) and the average rate increased from 0.6
(95% CI: 0.5, 0.8) to 0.9 (95% CI: 0.7, 1.0) per child-year when using a 4-fold IgG change criteria
because of substantial IgG boosting and waning above the seropositivity cutoff (Figure 4). Sensitivity
analyses that defined incident boosting over a range of 2-fold to 10-fold increases in IgG showed
force of infection estimates were relatively stable across a wide range of definitions. In Haiti, the only
pathogen for which force of infection estimated using a 4-fold increase in IgG was significantly
higher than the seroconversion rate was Cryptosporidium (Supplementary file 5).
We evaluated whether model-based force of infection estimates from age-structured seropreva-
lence could accurately recover estimates from the longitudinal analyses. We focused on the Kenya
cohort since children were measured repeatedly during the ages of primary infection and because
longitudinal force of infection and seroreversion rate estimates varied considerably across pathogens
(Figure 5). We estimated force of infection from seroprevalence curves using methods developed
for cross-sectional, ‘current status’ data, a common approach in serosurveillance of vaccine prevent-
able diseases (Hens et al., 2012), malaria (Corran et al., 2007), and dengue (Ferguson et al., 1999;
Katzelnick et al., 2018). Force of infection estimates from semiparametric spline models were simi-
lar to estimates from the longitudinal analysis for all pathogens, but had substantially wider confi-
dence intervals owing to the loss of information from ignoring the longitudinal data structure
(Figure 6). Parametric approaches including an exponential survival model (Jewell and Laan, 1995)
and a reversible catalytic model (Corran et al., 2007) yielded narrower confidence intervals than the
semiparametric model but tended to underestimate force of infection compared with longitudinal
estimates (Figure 6). Across pathogens, model-based force of infection estimates derived from sero-
prevalence were rank-preserving compared with nonparametric longitudinal analyses.
We conducted a simulation study to investigate whether longer sampling intervals in the cohorts
(6 months in Kenya, 12 months in Haiti) could lead us to miss more frequent exposures and thus
under-estimate force of infection. For each cohort, we created 100 imputed datasets that recon-
structed a child’s daily IgG levels, assuming that each infection boosted IgG and that it would wane
exponentially. The simulation drew IgG boosts from empirical distributions in each cohort and used
antibody-specific decay rates. We allowed for the maximum number of intermediate exposures
between measurements as long as IgG levels could wane sufficiently to follow a child’s empirical
Figure 3 continued
previously published (Arnold et al., 2017). Figure 3—figure supplement 1 includes similar curves from Kenya; Figure 3—figure supplement 2
includes similar curves from Tanzania.
DOI: https://doi.org/10.7554/eLife.45594.009
The following figure supplements are available for figure 3:
Figure supplement 1. Age dependent mean IgG and seroprevalence in Kenya.
DOI: https://doi.org/10.7554/eLife.45594.010
Figure supplement 2. Age dependent mean IgG and seroprevalence in Tanzania.
DOI: https://doi.org/10.7554/eLife.45594.011
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Figure 4. Longitudinal changes in IgG response over six repeated measurements among 142 children ages 0–11 years in Leogane, Haiti, 1990 – 1999.
Measurements were spaced by approximately 1 year (median spacing = 1, IQR = 0.7, 1.3). Horizontal dashed lines mark seropositivity cutoffs for each
antibody. The number of children measured at each visit was: n1 = 142, n2 = 142, n3 = 140, n4 = 131, n5 = 111, n6 = 66); 29 children had >6
measurements that are not shown. IgG response measured in multiplex using median fluorescence units minus background (MFI-bg) on the Luminex
Figure 4 continued on next page
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measurements, thus providing an approximate upper bound of the seroconversion rates (force of
infection) that could plausibly be detected for each antibody. We down-sampled the daily datasets
at intervals of 30, 90, 180, and 360 days to reflect realistic measurement intervals and estimated
seroconversion rates. We found that for most pathogens studied, higher resolution sampling would
not substantially increase seroconversion rates in absolute terms. Rates estimated through simulation
increased from between 0.1 to 0.9 episodes per child-year at risk if measured with a sampling inter-
val of 30 days instead of annually (Haiti) or every six months (Kenya). However, for pathogens with
highest seroconversion rates, ETEC and Campylobacter, increases in rates estimated with 30 day
sampling intervals detected a median of 4 to 8 additional seroconversions per child-year at risk com-
pared with empirical rates (Figure 7). In relative terms, seroconversion rates in Haiti had a larger dis-
crepancy; rates more than doubled when using a 30 day sampling interval, compared with the
annual interval used in the study.
Discussion
In cohorts from Haiti, Kenya, and Tanzania we identified consistent patterns in IgG responses that
provide new insights into enteropathogen seroepidemiology among children in low-resource set-
tings. Most population-level heterogeneity in IgG levels and seroconversion was between birth and
3 years, reflecting high transmission and early life primary infection. For particularly high transmission
pathogens (e.g., ETEC, Campylobacter), most variation in IgG levels was observed among chil-
dren < 1 year old. In these study populations, endemic force of infection for enteropathogens was
as high, and in many cases several fold higher, than force of infection estimated during epidemics of
new dengue serotype introductions in Nicaragua and Peru (approximately 0.4 to 0.6 seroconversions
per year) (Katzelnick et al., 2018; Reiner et al., 2014). Significant boosting and waning of antibody
levels above seropositivity cutoffs identified through longitudinal profiles in Haiti and Kenya rein-
force the value of longitudinal designs to derive antibody distributions among unexposed and to
estimate force of infection.
The shift of IgG distributions from bimodal to unimodal for many pathogens (Giardia, Cryptospo-
ridium, E. histolytica, and Campylobacter), resulting from a combination of antibody boosting, wan-
ing and acquired immunity, complicates the interpretation of seroprevalence at older ages: among
older children a seronegative response could either mean the children were never exposed or they
were previously exposed but antibody levels waned below seropositivity cutoffs. The age-dependent
shift contrasts with more stable differentiation of seronegative and seropositive groups observed for
some other antibody responses (e.g., C. trachomatis pgp3 in Figure 1—figure supplement 2) and
likely results from less robust and sustained IgG response following infection. Estimates of IgG half-
life in the Haiti cohort were on the order of 10 weeks for most pathogens (Supplementary file 8),
implying that time to seroreversion would be approximately 1 year without additional exposure
(assuming exponential decay l = 0.01 corresponding to a 10 week half-life, a starting level of 10,000
MFI, and seropositivity cutoff of 300 MFI; t ¼   log Nt=N0ð Þ=l= 350 days). Seroreversion is therefore
Figure 4 continued
platform. Created with notebook (https://osf.io/vyhra), which includes additional visualizations, and data (https://osf.io/3nv98). Figure 4—figure
supplement 1 includes a similar figure from the Kenya cohort. Figure 4—figure supplements 2 and 3 summarize the proportion of children in each
category across measurement rounds in Haiti and Kenya.
DOI: https://doi.org/10.7554/eLife.45594.012
The following figure supplements are available for figure 4:
Figure supplement 1. Longitudinal changes in IgG response between enrollment and follow-up among 205 children ages 4–17 months in Asembo,
Kenya, 2013.
DOI: https://doi.org/10.7554/eLife.45594.013
Figure supplement 2. Proportion of children ages 0–11 years with different longitudinal changes in IgG response over six repeated measurements in
Leogane, Haiti, 1990 – 1999.
DOI: https://doi.org/10.7554/eLife.45594.014
Figure supplement 3. Proportion of children ages 4–17 months with different longitudinal changes in IgG response between enrollment and follow-up
6 months later in Asembo, Kenya, 2013.
DOI: https://doi.org/10.7554/eLife.45594.015
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Figure 5. Average force of infection versus seroprevalence for enteropathogens measured in the Kenya and Haiti cohorts. Force of infection estimated
from prospective seroconversion rates. Vertical lines indicate 95% confidence intervals. Created with notebook (https://osf.io/jp9kf) and data (https://
osf.io/2q7zg, https://osf.io/3nv98). Figure 5—figure supplement 1 includes estimates from Haiti stratified by age bands.
DOI: https://doi.org/10.7554/eLife.45594.016
The following figure supplement is available for figure 5:
Figure supplement 1. Average force of infection versus seroprevalence for enteropathogens measured in the Haiti cohort, stratified by different age
bands.
DOI: https://doi.org/10.7554/eLife.45594.017
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possible at young ages, but population-level mean IgG levels and seroprevalence declined for only
three pathogens, Giardia, ETEC, and Campylobacter, and only above age 3 years (Figure 3, Fig-
ure 3—figure supplement 2). Increases in mean IgG levels and seroprevalence with age imply IgG
boosting from new infections or repeated infections outpaced IgG decay for all enteropathogens
studied until at least age 3 years, and for many pathogens through age 10 years; seroprevalence
thus reflects a conservative lower bound of a population’s cumulative exposure over this age range.
The age range over which seroprevalence provided useful epidemiologic information varied by
pathogen and cohort. In Haiti, 100% of children were seropositive to ETEC LT B toxin before age 12
months, though seroprevalence did not exceed 90% for most other pathogens until age 5 years in
Haiti (Figure 3). In Kenya, the age range of 4–18 months captured wide variation in seroprevalence
for most pathogens. The Tanzania study enrolled children ages one and older due to a primary focus
on trachoma monitoring, but missed the key window of variation in antibody response for all entero-
pathogens except E. histolytica and Salmonella (Figure 3—figure supplements 1 and 2). Studies
that extend beyond 10 years into adolescence and adulthood would help determine whether entero-
pathogen seroprevalence remains sufficiently high that it no longer provides useful epidemiologic
information. The shift in IgG distributions for some enteropathogens raises the question of whether
population mean IgG levels stabilize at a new ‘set point’ with repeated infections as has been
observed for dengue serotypes (Salje et al., 2018); if so, then the use of fold-changes in IgG would
be preferred to seropositivity cutoffs to identify incident infections among older ages.
In low-resource settings, measuring a sufficient number of young children before primary infec-
tion, preferably with longitudinal measurements, will help ensure that within-sample seropositivity
cutoff estimation is possible. Two-component mixture models fit the data and provided reasonable
cutoff estimates only when restricted to an age range that included clearly delineated subpopula-
tions of seronegative and seropositive responses. For most pathogens studied, this required meas-
urements among children < 1 year old, an age range during which IgG responses still followed a
Table 2. Incidence rates of seroconversion and seroreversion per child year among children ages 0–11 years in Haiti, 1990–1999.
Seropositivity cutoff * 4-Fold change in IgG levels †
Pathogen
Child-
years
Incident
cases
Rate
(95% CI)
Child-
years
Incident
cases
Rate
(95% CI)
Ratio of
cases
Ratio of
rates
Seroconversion/boosting
Giardia VSP-3 or VSP-5 269.6 108 0.40 (0.34, 0.48) 277.2 120 0.43 (0.35, 0.54) 1.1 1.1
Cryptosporidium Cp17 or
Cp23
109.3 70 0.64 (0.54, 0.77) 241.0 204 0.85 (0.73, 0.97) 2.9 1.3
E. histolytica LecA 283.7 97 0.34 (0.28, 0.42) 297.1 107 0.36 (0.29, 0.45) 1.1 1.1
Salmonella LPS groups B or D 132.1 75 0.57 (0.47, 0.68) 226.8 149 0.66 (0.54, 0.80) 2.0 1.2
ETEC LT B subunit 9.7 11 1.13 (0.75, 1.82) 32.1 32 1.00 (0.70, 1.45) 2.9 0.9
Norovirus GI.4 213.0 80 0.38 (0.30, 0.47) 254.3 107 0.42 (0.34, 0.53) 1.3 1.1
Norovirus GII.4.NO 105.8 67 0.63 (0.51, 0.80) 147.2 100 0.68 (0.54, 0.86) 1.5 1.1
Seroreversion/waning
Giardia VSP-3 or VSP-5 441.6 91 0.21 (0.17, 0.25) 290.9 127 0.44 (0.35, 0.54) 1.4 2.1
Cryptosporidium Cp17 or
Cp23
586.1 29 0.05 (0.03, 0.07) 273.5 171 0.63 (0.53, 0.74) 5.9 12.6
E. histolytica LecA 395.2 43 0.11 (0.08, 0.15) 310.4 67 0.22 (0.16, 0.27) 1.6 2.0
Salmonella LPS groups B or D 544.3 25 0.05 (0.03, 0.07) 344.5 89 0.26 (0.20, 0.32) 3.6 5.6
ETEC LT B subunit 702.1 2 0.00 (0.00, 0.01) 649.7 22 0.03 (0.02, 0.05) 11.0 11.9
Norovirus GI.4 464.9 28 0.06 (0.03, 0.09) 362.2 56 0.15 (0.11, 0.21) 2.0 2.6
Norovirus GII.4.NO 574.3 19 0.03 (0.02, 0.05) 477.9 39 0.08 (0.06, 0.11) 2.1 2.5
*Incident changes in serostatus defined by crossing seropositivity cutoffs.
†Incident changes in serostatus defined by a 4-fold increase or decrease in IgG levels (MFI-bg), with incident boosting episodes restricted to changes that
ended above the seropositivity cutoff and incident waning episodes restricted to changes that started from above the seropositivity cutoff.
DOI: https://doi.org/10.7554/eLife.45594.018
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bimodal distribution. The only reliable approach to estimate seropositivity cutoffs for the highest
transmission pathogens like ETEC and Campylobacter was to estimate a distribution among pre-
sumed unexposed by identifying measurements among children who subsequently experienced a
large increase in IgG, a strategy only possible in a longitudinal design. Although not attempted
here, studies that wish to compare antibody response and seroprevalence between different sites
should use a common assay platform and materials (e.g., shared bead coupling) with jointly esti-
mated seropositivity cutoffs to help ensure comparability across sites, since there are currently no
global reference standards to translate arbitrary units into antibody titers for enteropathogens.
Seroepidemiologic measures that can be estimated from cross-sectional surveys are of particular
interest for infectious diseases because most large-scale, population-based serosurveillance plat-
forms use cross-sectional designs (Arnold et al., 2018). Our results show that seroprevalence and
force of infection estimated from seroprevalence models adequately summarize between-pathogen
heterogeneity in transmission when compared with longitudinal estimates of force of infection.
Pathogens with fastest rising mean IgG and seroprevalence with age (e.g., ETEC, Campylobacter,
norovirus GII.4; Figure 3, Figure 3—figure supplement 1) had highest force of infection measured
prospectively over the study period, and seroprevalence was rank-preserving with prospective force
of infection in both Haiti and Kenya (Figure 5). Seroprevalence alone thus appears to be sufficient to
assess relative pathogen transmission if measured in an age range that captures ample heterogene-
ity in response (in these cohorts < 3 years old). Our findings align with modeling studies of other
infectious diseases such as malaria (Corran et al., 2007), trachoma (Pinsent et al., 2018), and den-
gue (Katzelnick et al., 2018), and suggest that enteropathogens share similar seroepidemiologic
features conducive to population-based surveillance in cross-sectional surveys despite different
seroconversion (force of infection) seroreversion
0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7
E. histolytica LecA
Salmonella LPS groups B or D
Giardia VSP-3 or VSP-5
Cryptosporidium Cp17 or Cp23
ETEC LT B subunit
Campylobacter p18 or p39
rate per child-year at risk
method
Longitudinal
Cross sectional, spline
Cross sectional, RCM
Cross sectional, exponential
Figure 6. Enteropathogen seroconversion and seroreversion rates among 205 children ages 4 to 17 months measured longitudinally in Asembo, Kenya,
2013. The seroconversion rate is a measure of a pathogen’s force of infection. Longitudinal estimates are non-parametric rates of incident
seroconversions and seroreversions among children at risk, assumed to occur at the midpoint of the measurement interval. Cross-sectional estimators
were derived from age-specific seroprevalence curves using semiparametric cubic splines (spline), a reversible catalytic model (RCM) that assumed
constant seroconversion and seroreversion rates with the seroreversion rate estimated from prospective data, and a parametric constant rate survival
model (exponential). Error bars mark 95% confidence intervals. IgG response measured in multiplex using median fluorescence units minus background
(MFI-bg) on the Luminex platform (N = 410 measurements from 205 children). Created with notebooks (https://osf.io/sqvj7, https://osf.io/j9nh3) and
data (https://osf.io/2q7zg).
DOI: https://doi.org/10.7554/eLife.45594.019
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underlying immunology. Two caveats are that cross-sectional methods considered in this study will
generally underestimate force of infection because they fail to rigorously account for seroreversion
and incident boosting above seropositivity cutoffs (Figure 6), and seroprevalence is not a clear
marker of cumulative exposure as children age beyond the window of primary infection because of
waning IgG responses.
The relative intensity of pathogen transmission based on serological measures in this analysis
aligns with relative differences in infection from large-scale molecular testing in stool. For example,
rapid rises in IgG levels, seroprevalence, and force of infection for ETEC and Campylobacter begin-
ning very early in life is consistent with their prominence in molecular testing of stool specimens in
the MAL-ED studies (Platts-Mills et al., 2018; Platts-Mills et al., 2015). Higher force of infection for
norovirus GII.4 compared with norovirus GI.4 in Haiti is consistent with the relative prominence of cir-
culating genogroups (Ba´nyai et al., 2018; Rouhani et al., 2016). The results lend additional support
to the idea that broader serological testing in existing serosurveillance platforms represents a useful
opportunity to measure enteropathogen transmission in populations without routine stool-based
testing (Metcalf et al., 2016; Arnold et al., 2018).
These analyses had limitations. High correlation between Salmonella LPS Groups B and D,
between ETEC LT B subunit and cholera toxin B subunit, and between norovirus GI and norovirus
GII at the individual level (Figure 2) shows that for these pathogens seroepidemiologic analyses will
be less specific than analyses based on molecular detection. Salmonella LPS Groups B and D have
antigenic overlap in their lipopolysaccharides (Grimont and Weill F-X, 2007), and ETEC LT B subunit
and cholera toxin B subunit are known to be immunologically cross-reactive (Smith and Sack, 1973).
There was no known cholera transmission in the study populations, so we assumed the elevated
responses to the cholera toxin B subunit reflected exposure to LT-producing ETEC; this assumption
could only be confirmed with specific measures of cholera infection. Norovirus GI and GII virus-like
particles are antigenically different, but cross-reactivity between norovirus genogroups is possible
(Tamminen et al., 2012). In addition, a recent study from Uganda found high seroprevalence for
both GI and GII norovirus suggesting repeated infections by viruses of the same or different gen-
ogroup could potentially boost cross-reactive antibody production (Thorne et al., 2018). Despite
lower specificity between genogroups or serogroups in these cases, the consistency of antibody rela-
tionships with predictions based on antigenic overlap, and absence of correlation between unrelated
antibodies (Supplementary file 3), lends support to the internal validity of the assays.
Our reliance on IgG as a sole measure of immune response did not enable finer distinction
between pathogens in age-dependent acquired immunity that might be possible with additional
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Figure 7. Empirical seroconversion rates compared with estimates from 100 simulated datasets with daily resolution IgG trajectories that were sampled
at a 30 day interval before estimating seroconversion rates. Vertical lines in the simulation results indicate medians. (A) In the Kenya cohort, children
were ages 4–18 months and empirical IgG measurements were measured every 6 months (approximately 180 days). (B) In the Haiti cohort, children
were ages 0–11 years, and empirical IgG measurements were measured approximately each year (median spacing = 1 year, IQR = 0.7, 1.3). Created
with notebooks (https://osf.io/qmdf2, https://osf.io/9fxhb) and data (https://osf.io/2q7zg, https://osf.io/3nv98).
DOI: https://doi.org/10.7554/eLife.45594.020
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measures of immune function. For example, ETEC LT and Campylobacter IgG levels and seropreva-
lence consistently rose quickly by age 1 year across all of the cohorts (Figure 3 and its supplements).
We interpret the steep rise in IgG early in life to reflect higher transmission and exposure to ETEC
and Campylobacter compared with other pathogens studied, but the steeper rise in IgG levels could
also reflect a difference in immune mechanism. For example, it could reflect a more robust response
to T-cell dependent antigens compared with T-cell independent antigens (e.g., Salmonella LPS),
which might require a more mature immune system to mount a robust B-cell response (Siegrist and
Aspinall, 2009). Yet, the steep rise in Salmonella LPS IgG among Haitian children (Figure 3), and
the faster age-dependent rise in IgG response to Salmonella LPS compared with ETEC LT B subunit
among children in the United States (Arnold et al., 2017) suggest that differences in IgG acquisition
by age likely reflect differences in early life pathogen exposure.
Children were measured relatively infrequently in the Kenya and Haiti cohorts, which could have
led to missed seroconversions if IgG levels waned below the seropositivity cutoff before a child’s
next measurement. Our simulations that studied the effect of more frequent sampling showed that
monthly measurement could lead to higher force of infection estimates in settings with frequent
exposure, and that more frequent measurements would be most valuable for highest transmission
pathogens, such as ETEC and Campylobacter in this study (Figure 7). Higher resolution longitudinal
measurements would also enable study of seasonal differences in enteropathogen transmission.
Measurement timing in analysis populations precluded extensive evaluation of seasonal differences
in IgG response, but age-adjusted seroprevalence was 1–5% higher across pathogens during the
wet season in the Haiti cohort (Supplementary file 1). This exploratory result suggests a potential
avenue of future research that could join high resolution temperature, precipitation, and antibody
measurements to study seasonal drivers of enteropathogen transmission dynamics.
Another limitation is that without measures of patent infection in stool we were unable to com-
pare multiple independent measures of transmission. Paired stool and blood specimens could help
resolve some of the questions raised above related to serological assay specificity and differential
immune development across pathogens. The Haiti and Tanzania cohorts were not originally
designed to assess enteropathogens, and antibody measurements were not paired with measures of
clinical symptoms of diarrhea or with measures of patent infection in stool. In Haiti, Moss et al.
(2014) previously reported limited microscopy testing for protozoan cysts alongside IgG markers,
but infrequent stool measurements prevented extensive comparisons. In Kenya, diarrheal stool test-
ing during weekly follow-up visits for Cryptosporidium and Giardia showed that serology identified
nearly all infections detected in stool, plus a substantial number of presumed infections not detected
through diarrheal surveillance (Supplementary file 4); however, for other pathogens studied we did
not have stool-based measures of infection. All included antigens have been characterized exten-
sively with respect to patent infections among adults and children in other settings (details in Materi-
als and methods). Furthermore, we observed high levels of consistency across cohorts in
seroepidemiologic patterns, and consistency with general age-dependent patterns documented
across diverse pathogens for which transmission begins early in life (Arnold et al., 2017;
Hens et al., 2012; Corran et al., 2007; Katzelnick et al., 2018). Together, these observations sug-
gest that the antibody dynamics and force of infection estimates from IgG responses reflect actual
pathogen transmission in these cohorts, but paired stool and blood testing would provide a more
definitive test.
High-resolution, longitudinal assessment of paired enteropathogen infection and antibody meas-
urements among children could provide valuable, additional insights into the pathogen-specific anti-
body dynamics following primary- and secondary infections. Analyses of Plasmodium falciparum
(White et al., 2014; Helb et al., 2015; Rodriguez-Barraquer et al., 2018) and dengue virus
(Salje et al., 2018) illustrate how paired, longitudinal measurements of patent infection and antibody
response enable richer characterizations of antibody dynamics and pathogen transmission. Paired
longitudinal stool and antibody testing among children and adults would enable studies of age-
dependent enteropathogen antibody kinetics, and if present, disentangle them from age-varying
incidence rates when using serology to estimate force of infection. Studies that pair stool-based
molecular testing with antibody response could also assess whether approaches to estimate entero-
pathogen incidence from cross-sectional samples that rely on estimates of antibody decay with time
since infection (Teunis et al., 2012; Simonsen et al., 2009) could be used among children in low-
resource settings. A similar approach was recently described to estimate cholera incidence among
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all ages (Azman et al., 2019), but broader development across enteropathogens and among young
children remains an open area of research.
Conclusions
Among children in Haiti, Kenya, and Tanzania, antibody-based measures of enteropathogen infec-
tion reflected high transmission with primary exposure to most pathogens occurring by age 1–2
years. In low-resource populations, seroincidence rates and force of infection estimated beyond the
age range of primary infection ideally should account for IgG boosting and waning above seroposi-
tivity cutoffs. Antibodies are a promising approach to measure population-level enteropathogen
infection, and seroepidemiologic measures of heterogeneity and transmission are central considera-
tions for their use in trials or in serologic surveillance. Our findings show that for most enteropatho-
gens studied, the ideal window to measure heterogeneity in antibody response closes by ages 2 to
5 years in low-resource settings, and studies that plan to estimate force of infection should favor lon-
gitudinal designs with multiple measurements in this early age window.
Materials and methods
Key resources table
Reagent type
or resource Designation Source or reference Identifiers
Additional
information
Peptide,
recombinant protein
Giardia intestinalis VSP-3 PMID: 17901334
PMID: 20876825
GenBank: XM_001707314 Dr. Jeffrey Priest (CDC)
Peptide,
recombinant protein
Giardia intestinalis VSP-5 PMID: 11500396
PMID: 20876825
GenBank: AF354538.1 Dr. Jeffrey Priest (CDC)
Peptide,
recombinant protein
Cryptosporidium Cp17 PMID: 10699255
PMID: 15165066
GenBank: AF114166 Dr. Jeffrey Priest (CDC)
Peptide,
recombinant protein
Cryptosporidium Cp23 PMID: 8892291
PMID: 10203492
GenBank: U34390 Dr. Jeffrey Priest (CDC)
Peptide,
recombinant protein
Entamoeba
histolytica LecA
PMID: 2000392
PMID: 14741152
PMID: 24591430
GenBank: M60498 Dr. William Petri
(University of Virginia)
and
Dr. Joel Herbein (TechLab)
Peptide,
recombinant protein
Campylobacter
jejuni p18
PMID: 8576327
PMID: 16014430
GenBank: X83374 Dr. Jeffrey Priest (CDC)
Peptide,
recombinant protein
Campylobacter
jejuni p39
PMID: 10688204
PMID: 16014430
GenBank: CAL34198.1 Dr. Jeffrey Priest (CDC)
Peptide,
recombinant protein
ETEC heat labile
toxin B subunit
PMID: 3882744
PMID: 18494692
Sigma-Aldrich
Peptide,
recombinant protein
Cholera toxin
B subunit
PMID: 3882744 Sigma-Aldrich
Peptide,
recombinant protein
Salmonella
enterica LPS group B
PMID: 2567429
PMID: 17329442
Sigma-Aldrich
Peptide,
recombinant protein
Salmonella
enterica LPS group D
PMID: 2567429
PMID: 17329442
Sigma-Aldrich
Peptide,
recombinant protein
Norovirus GI.4
Virus Like Particles
This paper Dr. Jan Vinje (CDC)
Peptide,
recombinant protein
Norovirus GII.4.NO
Virus Like Particles
This paper Dr. Jan Vinje (CDC)
Ethics statement
In Haiti, the human subjects protocol was reviewed and approved by the Ethical Committee of St.
Croix Hospital (Leogane, Haiti) and the institutional review board at the US Centers for Disease Con-
trol and Prevention (CDC). After listening to an overview of the study, individuals were asked for ver-
bal consent to participate. Verbal consent was deemed appropriate by both review boards because
of low literacy rates in the study population. With each longitudinal visit, the study team re-con-
sented participants before specimen collection. Mothers provided consent for children under 7, and
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children 7 years and older provided additional verbal assent. In Kenya, the human subjects protocol
was reviewed and approved by institutional review boards at the Kenya Medical Research Institute
(KEMRI) and at the US CDC. Primary caretakers provided written informed consent for their infant
child’s participation in the trial and blood specimen collection and testing (Morris et al., 2018). The
original trial was registered at clinicaltrials.org (NCT01695304). In Tanzania, the human subjects pro-
tocol was reviewed and approved by the Institute for Medical Research Ethical Review Committee in
Dar es Salaam, Tanzania and the institutional review board at the US CDC. Parents of enrolled chil-
dren provided consent, and children 7 years and older also provided verbal assent before specimen
collection.
Multiplex bead assays
Antigens
All antigens used have been well-characterized in previous studies. Lipopolysaccharides (LPS) from
Group D Salmonella enterica serotype Enteritidis (Strid et al., 2007), LPS from Group B S. enterica
serotype Typhimurium (Strid et al., 2007), and recombinant heat labile toxin B subunit protein
(Arnold et al., 2017; Levine et al., 1985; Flores et al., 2008) from enterotoxigenic Escherichia coli
(ETEC LT B subunit) were purchased from Sigma Chemical (St. Louis, MO). Recombinant Giardia
VSP-3 and VSP-5 (Bienz et al., 2001 Morrison et al., 2007) and Cryptosporidium Cp17 and Cp23
antigens (Perryman et al., 1996; Priest et al., 1999; Priest et al., 2000) were expressed and puri-
fied as previously described (Priest et al., 2010; Moss et al., 2004). Recombinant Campylobacter
p18 and p39 antigens (Burnens et al., 1995; Parkhill et al., 2000; Schmidt-Ott et al., 2005) were
expressed and purified as previously described (Zambrano et al., 2017). E. histolytica LecA antigen
(Moss et al., 2014; Tannich et al., 1991; Houpt et al., 2004) was kindly provided by William Petri
(University of Virginia) and Joel Herbein (TechLab). Virus-like particles from norovirus GI.4 and GII.4
New Orleans were purified from a recombinant baculovirus expression system (Arnold et al., 2017;
Jiang et al., 1992; Pisanic et al., 2019). All antibody responses were measured in multiplex bead
assays on the Luminex platform at the United States Centers for Disease Control and Prevention:
Haiti study (PJL’s laboratory), Kenya study (JWP’s laboratory), and Tanzania study (DLM’s
laboratory).
Haiti
Sera from the Haiti cohort study were diluted 1:400 and analyzed by multiplex bead assay as
described in detail elsewhere (Moss et al., 2014; Arnold et al., 2017; Hamlin et al., 2012). Salmo-
nella LPS and ETEC LT B subunit antigens were coupled to SeroMap (Luminex Corp, Austin, TX)
beads in buffer containing 0.85% NaCl and 10 mM Na2HPO4 at pH 7.2 (PBS) using 120 micrograms
for 1.25  107 beads using the methods described by Moss and colleagues (Moss et al., 2011).
Coupling conditions and externally defined cutoff values for the Giardia, Cryptosporidium, and E.
histolytica antigens as well as for the Schistosoma japonicum glutathione-S-transferase (GST) nega-
tive control protein have been previously reported (Moss et al., 2014). Each multiplex bead assay
plate (N = 25) included four control sera: one negative sample and three positive samples that
spanned the response range from low to high for a selection of the antigen markers. For the positive
control sample responses to the 10 enteric antigens used in this study, the average coefficient of var-
iation (CV%) was 8.3 with a standard deviation of 4.3. The median CV% was 7.9 with a range of 2.3%
to 19.9%.
Kenya
For the Kenya study, an optimized bead coupling technique using less total protein was performed
in buffer containing 0.85% NaCl and 25 mM 2-(N-morpholino)-ethanesulfonic acid at pH 5.0. The B
subunit protein from cholera toxin was purchased from Sigma Chemical. The GST negative control
protein (15 mg), Cryptosporidium Cp17 (6.8 mg) and Cp23 (12.5 mg) proteins and the Campylobacter
p39 protein (25 mg) were coupled to 1.25  107 beads using the indicated protein amounts
(Zambrano et al., 2017). The Giardia, E. histolytica, ETEC, cholera, and Campylobacter p18 proteins
were coupled using 30 mg of protein per 1.25  107 beads. Salmonella LPS B and LPS D were cou-
pled to the same number of beads using 60 mg and 120 mg, respectively. Blood spot elutions from
the Kenya study were diluted to a final serum concentration of 1:400 (assuming 50% hematocrit) and
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analyzed by multiplex bead assay as described by Morris and colleagues (Morris et al., 2018). Each
multiplex bead assay plate (N = 11) included five control sera: one negative sample and four positive
control samples offering a range of responses to various antigen markers. For the positive control
sample responses to the 11 enteric antigens used in this study, the average CV% was 6.3 with a stan-
dard deviation of 3.7. The median CV% was 5.3 with a range of 1.1% to 14.9%.
Tanzania
For the Tanzania study, the same conditions described in the Kenya study were used to couple anti-
gens from Giardia, Cryptosporidium, E. histolytica, ETEC B toxin subunit, cholera B toxin subunit,
GST, and Salmonella LPS group B and LPS group D. Campylobacter p39 and p18 were both coupled
at 25 mg per 1.25  107 beads in buffer containing 0.85% NaCl and 25 mM 2-(N-morpholino)-etha-
nesulfonic acid at pH 5.0. Dried blood spots were eluted in the casein-based buffer described previ-
ously (Priest et al., 2010) and samples were diluted to either 1:400 serum dilution with 50 ml run per
well for year 1, or 1:320 serum dilution with 40 ml run per well for years 2–4. The incubation steps,
washes, and data collection methods used in the multiplex bead assay were performed as described
previously (Priest et al., 2010). All samples were run in duplicate, and the average median fluores-
cence intensity minus background (MFI-bg) value was recorded. Each multiplex bead assay plate
(N = 37) included four control sera: one negative sample and three positive control samples offering
a range of responses to various antigen markers. For the positive control sample responses to the
nine enteric antigens used in this study, the average CV% was 8.4 with a standard deviation of 5.3.
The median CV% was 5.3 with a range of 2.6 to 15.1. The Tanzania study used different bead lots in
year 1 and years 2–4; we confirmed that the use of different bead lots had no influence on the
results (Supplementary file 1).
Antibody distributions and determination of seropositivity
We transformed IgG levels to the log10 scale because the distributions were highly skewed. Means
of the log-transformed data represent geometric means. We summarized the distribution of log10
IgG response using kernel density smoothers. In the Tanzania and Haiti cohorts, where children were
measured across a broad age range, we stratified IgG distributions by each year of age <3 years to
examine age-dependent changes in the population distributions. To assess potential cross-reactivity
between antigens, we estimated pairwise correlations between individual-level measurements in
each cohort using a Spearman rank correlation (Zar, 2005) and visualized the relationship for each
pairwise combination with locally weighted regression fits (Cleveland and Devlin, 1988).
We compared three approaches to estimate seropositivity cutoffs. Approach 1: External known
positive and negative specimens were used to determine seropositivity cutoffs for Giardia VSP-3 and
VSP-5 antigens, Cryptosporidium Cp17 and Cp23 antigens, and E. histolytica LecA antigen. Cutoffs
were determined using ROC analysis as previously described (Moss et al., 2014; Morris et al.,
2018) for all antigens except for LecA, VSP-3, and VSP-5 in Haiti; in these cases, the mean plus three
standard deviations of 65 specimens from citizens of the USA with no history of foreign travel were
used to estimate cutoffs (Moss et al., 2014). Approach 2: We fit a 2-component, finite Gaussian mix-
ture model (Benaglia et al., 2009) to the antibody distributions among children 0–1 years old, and
estimated seropositivity cutoffs using the lower component’s mean plus three standard deviations.
The rationale for restricting the mixture model estimation in Haiti and Tanzania to children 0–1 years
old was based on initial inspection of the age-stratified IgG distributions that revealed a shift from
bimodal to unimodal distributions by age 3 (Figure 1). This approach ensured that there was a suffi-
ciently large fraction of unexposed children in the sample to more clearly estimate a distribution
among seronegative children. Approach 3: In the longitudinal Haiti and Kenya cohorts we identified
children < 1 year old who presumably seroconverted, defined as an increase in MFI-bg values of
+two or more on the log10 scale. A sensitivity analysis showed that an increase of 2 on the log10
scale was a conservative approach to identify seroconversion for most antibodies considered in this
study; an increase of between 0.3 to 2.16 MFI-bg lead to optimal agreement with ROC-based and
mixture model-based classifications in Kenya, and an increase of 0.92 to 2.41 led to optimal agree-
ment across antigens and references in Haiti (Supplementary file 5). We then used the distribution
of measurements before seroconversion to define the distribution of IgG values among the pre-
sumed unexposed. We used the mean log10 MFI-bg plus three standard deviations of the presumed
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unexposed distribution as a seropositivity cutoff. We summarized the proportion of observations
that were in agreement between the three classification approaches, and estimated Cohen’s Kappa
(Cohen, 1960). Additional details and estimates of seropositivity cutoff agreement are reported in
Supplementary file 2. Mixture models failed to estimate realistic cutoff values if there was an insuffi-
cient number of unexposed children, which was the case for ETEC LT B subunit and cholera toxin B
subunit in all cohorts, and for nearly all antigens in Tanzania where the study did not enroll chil-
dren < 1 year old (Table 1).
In analyses of seroprevalence and seroconversion, we classified measurements as seropositive
using ROC-based cutoffs if available, and mixture model-based cutoffs otherwise. There were three
exceptions. By age 1 year, a majority of children across the cohorts had IgG levels near the maxi-
mum of the assay’s dynamic range for ETEC LT B toxin and cholera toxin B subunit. The absence of
a sufficient number of unexposed children to ETEC LT B toxin, cholera B toxin, and in some cases
Campylobacter p18 or p39 led mixture models either to not converge or to estimate unrealistically
high seropositivity cutoffs beyond the range of quantifiable levels. For these pathogens, we used
seropositivity cutoffs estimated from presumed unexposed measurements in the longitudinal Haiti
and Kenya cohorts (approach 3, above). High levels of agreement between classifications
(Supplementary file 2) meant results were insensitive to choice of approach in these cohorts. We
classified children as seropositive to Giardia, Cryptosporidium, Campylobacter, or Salmonella if anti-
body levels against either of the antigens from each pathogen were above estimated seropositivity
cutoffs.
Age-dependent antibody levels and seroprevalence curves
We estimated mean IgG levels and seroprevalence by age using semiparametric cubic splines in a
generalized additive model, specifying binomial errors for seroprevalence, and random effects for
children or clusters in the case of repeated observations (Wood, 2017; Wood, 2012). We also esti-
mated the relationships by age using a stacked ensemble approach called ‘super learner’ that
included a broader and more flexible library of machine learning algorithms (Arnold et al., 2017;
van der Laan et al., 2007; Polley et al., 2018), and found similar fits to cubic splines. We estimated
approximate, simultaneous 95% confidence intervals around the curves using a parametric bootstrap
from posterior estimates of the model parameter covariance matrix (Ruppert et al., 2003).
Supplementary file 6 includes additional details.
Force of infection from longitudinal data
In the Kenya and Haiti longitudinal cohorts, we estimated prospective seroconversion rates as a mea-
sure of force of infection by dividing the number of children who seroconverted by the person-time
at risk between measurements. We defined incident seroconversions and seroreversions as a change
in IgG across a pathogen’s seropositivity cutoff. Vaccine immunogenicity and pathogen challenge
studies among healthy adults often use a 4-fold increase in antibody levels (difference of +0.6 on the
log10 scale) as a criterion for seroconversion (Bernstein et al., 2015; Jin et al., 2017;
Chakraborty et al., 2018). In a secondary analysis aimed to capture significant changes above a
pathogen’s seropositivity cutoff, we defined incident boosting episodes as a  4 fold increase in IgG
to a final level above a seropositivity cutoff, and incident waning episodes as  4 fold decrease in
IgG from an initial level above a seropositivity cutoff. In the secondary definition, individuals were
considered at risk for incident boosting episode if they were seronegative, if they experienced a  4
fold increase in IgG in their first measurement period, or if they experienced a  4 fold decrease in
IgG in a preceding period (Haiti). To estimate person-time at risk used for rates and force of infec-
tion, we assumed incident changes were interval-censored and occurred at the midpoint between
measurements. We estimated 95% confidence intervals for rates with 2.5 and 97.5 percentiles of a
nonparametric bootstrap distribution (Wasserman, 2004) that resampled children with replacement
to account for repeated observations.
Force of infection from age-structured seroprevalence in Kenya
In the Kenya cohort, we estimated force of infection through age-structured seroprevalence using
multiple approaches. There is a long history methods development to estimate force of infection
from age-dependent seroprevalence (Hens et al., 2012), which is of particular interest to large-scale,
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cross-sectional surveillance platforms (Arnold et al., 2018). Our rationale was to determine if force
of infection estimates from age-structured seroprevalence were comparable to estimates from the
longitudinal analysis based on incident changes in serostatus.
As we show in Supplementary file 7, the age dependent seroprevalence curve is the difference
between the cumulative distribution functions of seroconversion times and seroreversion times. In a
special case of no seroreversion, age-specific seroprevalence is thus the cumulative hazard function.
The age-specific force of infection can then be estimated as the hazard of seroconverting at age
A = a: l(a) = F0(a) / [1 – F(a)], where F(a)=P(Y | A = a) is the proportion of the population who are
seropositive at age a and F0(a) is the derivative of F(a) with respect to a. Key assumptions include sta-
tionarity/homogeneity (i.e., no intervention or cohort effects) and that there is no seroreversion
(Hens et al., 2012). There was no evidence for large changes in transmission during the studies,
even due to intervention (Supplementary file 1). We know for many enteric pathogens children in
the Kenya cohort did serorevert (e.g., Figure 6); when assumption is violated, estimates provide a
lower-bound of a pathogen’s force of infection. We considered three different estimation
approaches for force of infection from age-structured seroprevalence.
Exponential model (SIR model)
The simplest catalytic model, a susceptible-infected-recovered (SIR) model, assumed a constant
force of infection over different ages, l(a) = l and no seroreversion (Hens et al., 2012). In the sur-
vival analysis context, this is equivalent to assuming a constant hazard, which can be estimated with
an exponential survival model. We modeled the probability of being seropositive conditional on age
with a generalized linear model fit with maximum likelihood that assumed a binomial error structure
and complementary log-log link (Jewell and Laan, 1995). We estimated average force of infection
from the model’s intercept term:
log  log 1 P Y ¼ 1jAð Þ½  ¼ log lþ log A
Reversible catalytic model (SIS model)
For some infectious diseases, like malaria, reversible catalytic models have been proposed to esti-
mate force of infection from an age-seroprevalence curve while accounting for antibody waning with
time since infection (Corran et al., 2007). The model assumes a constant rate of seroconversion, l,
but extends the SIR model by also assuming a constant seroreversion rate, r, equivalent to a suscep-
tible-infected-susceptible (SIS) model. We modeled the probability of a child being seropositive con-
ditional on age as a function of these two additional parameters:
P Y ¼ 1jAð Þ ¼
l
lþ 
1  exp   lþ ð Þ Að Þ½ 
We fit the model with maximum likelihood assuming a binomial error structure and a fixed serore-
version rate. To incorporate information about the seroreversion rate in the model, we bootstrapped
the dataset 1000 times, resampling children with replacement. In each bootstrap replicate, we esti-
mated each pathogen’s seroreversion rate using information from longitudinal data, and then fit the
reversible catalytic model assuming a cross-sectional sample. The results are thus optimistic because
they incorporate some information from the longitudinal design. Attempts to fit an SIS model assum-
ing only a cross-sectional design with the seroreversion rate as a second free parameter led to highly
unstable estimates, consistent with results presented in Supplementary file 7 that show age-depen-
dent seroprevalence alone does not technically contain information about seroreversion (r). As an
internal validity check, we confirmed that force of infection estimates from the SIS model matched
those from the SIR model for ETEC and Campylobacter, pathogens which had seroreversion rates
that approached 0.
Semiparametric spline model
We fit a model that allowed force of infection to vary flexibly by age using cubic splines in a general-
ized additive model (Wood, 2017). Let h P Y ¼ 1jAð Þ½  ¼ logit P Y ¼ 1jAð Þ ¼ g Að Þ for an arbitrary
function g ð Þ, which we fit with cubic splines that had smoothing parameters chosen through cross-
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validation. The age-specific prevalence predicted from the model is: P^ Y ¼ 1j A ¼ að Þ ¼ exp h^ að Þ½ 
1þ exp h^ að Þ½  and
the age-specific force of infection is:
l^ að Þ ¼ h^0 að Þ
exp h^ að Þ½ 
1þ exp h^ að Þ½ 
where h^0 að Þ is the first derivative of the linear predictor from the logit model (Hens et al., 2012).
We estimated h^0 að Þ and its standard error using finite differences from spline model predictions
(Wood, 2017; Wood, 2012). To estimate average force of infection from the model, comparable to
other methods used, for each pathogen we estimated the marginal average force of infection over
the empirical age distribution in the cohort:
l^¼
Z
a
l^ að ÞP A¼ að Þ
We estimated approximate 95% confidence intervals for the average force of infection by simula-
tion with a parametric bootstrap that was based on the posterior distribution of model parameters
(Ruppert et al., 2003; Marra and Wood, 2012). Supplementary file 7 provides additional details,
including age-specific estimates of force of infection for each pathogen.
Effects of sampling interval on serological force of infection estimates
We conducted a simulation study to investigate whether longer sampling intervals used in the Kenya
and Haiti cohorts could lead to under-estimates of seroconversion rates. We modeled a single anti-
gen per pathogen (e.g., Cp17 for Cryptosporidium). For each cohort, we created 100 simulated
datasets that imputed each child’s daily IgG levels. The simulation was designed provide an approxi-
mate upper bound on force of infection measured with serology. IgG levels were allowed to continu-
ously boost and wane as long as each child’s IgG trajectory remained consistent with their empirical
measurements. We drew IgG boosts for each antibody from the empirical distribution of >4 fold
increases in each cohort. We assumed IgG levels decayed exponentially. We estimated exponential
decay parameters for each antibody using a subsample of adjacent measurements separated by <1
year with the largest decline in IgG (bottom quintile of declines), selected to reduce the possibility
of intermediate exposures. IgG half-life estimates ranged from 51 to 169 days across antibodies in
Haiti. In Kenya, too few children experienced reductions in IgG between measures for us to reliably
estimate antibody decay rates, so the simulation assumed a fixed IgG decay rate across antibodies
that corresponded to a half-life of 69 days, which was broadly consistent with the majority of IgG
half-life estimates in Haiti and with 12 week half-life estimates for Cryptosporidium IgG levels among
Canadian adults (Priest et al., 2001).
After simulating daily IgG trajectories for all children, we down-sampled the imputed data at
intervals of 30, 90, 180, and 360 days and estimated seroconversion rates and seroreversion per the
main analysis. We found that sampling intervals of 30 days adequately summarized even the most
dynamic IgG trajectories. As an internal validity check, we compared seroconversion and serorever-
sion rates estimated from the simulations with empirical rates at comparable sampling intervals (180
days in Kenya, 360 days in Haiti) and found excellent agreement. Across the 100 simulated datasets,
we quantified the potential influence of measurement frequency on force of infection estimates by
estimating median rates for each pathogen and sampling interval, as well as the median difference
in rates between sampling intervals. Supplementary file 8 includes the full simulation and all details.
Data availability and replication files
Analyses were conducted in R version 3.5.3. Data and computational notebooks used to complete
the analyses are available through GitHub (Arnold, 2019; copy archived at https://github.com/elifes-
ciences-publications/enterics-seroepi) and the Open Science Framework (osf.io/r4av7).
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